Volume Alert - MRK 59.23 Merck & Company $MRK Hit a high today of 59.49 Closing the day 10:30 at 59.23 -0.14 -0.24% With a day low of 59.10 and a total volume of 1,146,185.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - 33 mins ago
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 108.72 (-0.19), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), AMGN: 162.18 (-0.24), MO: 49.31 (+0.03), CVX: 118.00 (-0.44)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 42.99 (-0.73), AGN: 196.23 (+0.89), HLF: 37.63 (+0.08), VRX: 130.90 (+0.87), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), LLY: 67.65 (-0.20)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), MRK: 59.20 (-0.17)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 59.20 (-0.17), NVS: 92.62 (-0.15)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.50 (-0.15), JNJ: 108.71 (-0.20), IDRA: 2.48 (-0.10), DERM: 16.07 (+0.04), MRK: 59.20 (-0.17), PFE: 30.42 (+0.10), AZN: 74.19 (-0.01), AMGN: 162.18 (-0.24), GSK: 45.45 (-0.51), HSP: 57.82 (+0.51), NVS: 92.62 (-0.15), CELG: 108.19 (+0.34)
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 107.19 (-0.82), MRK: 59.20 (-0.17)
Dow Index Dogs: 10% Bonus In 5 Lowest-Price, High-Yield Stocks
Fredrik Arnold - at Seeking Alpha - Tue Nov 11, 1:26PM CST
KO: 42.76 (+0.25), T: 35.38 (+0.28), GE: 26.56 (+0.18), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), MCD: 95.13 (-0.01), PG: 89.57 (-0.10), CVX: 118.00 (-0.44), VZ: 50.97 (+0.36), CSCO: 24.97 (-0.18)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - Tue Nov 11, 10:50AM CST
MRK: 59.20 (-0.17), AZN: 74.19 (-0.01), THRX: 13.27 (+0.34), TBPH: 17.88 (-0.08), GSK: 45.45 (-0.51)
Product and Pipeline Analysis of the Global Vaccines Market
M2 - Tue Nov 11, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/4nt5s9/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Vaccines Market " report to their offering. Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013. Key Findings:Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. - Vaccines are now available for prevention of about infectious diseases. - Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic. - Infectious disease vaccines-particularly viral vaccines-represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration. - One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases. - Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis. - The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction 4. Global Regulatory Oversight 5. Competitive Landscape 6. Competitive Landscape-Bacterial Vaccines 7. Competitive Landscape-Viral Vaccines 8. Competitive Landscape-Parasitic Vaccines 9. Competitive Landscape-Cancer Vaccines 10. Competitive Landscape-Allergy Vaccines 11. Competitive Landscape-Other Vaccines 12. Bacterial Vaccine Product Dashboard 13. Viral Vaccine Product Dashboard 14. Parasitic Vaccine Product Dashboard 15. Cancer Vaccine Product Dashboard 16. Allergy Vaccine Product Dashboard 17. Other Vaccine Products Dashboard 18. Timeline of Key Events 19. Conclusions Companies Mentioned - AFFiRiS - Archivel Farma - Biondvax - Bionor Pharma - Dendreon - GSK - Greer Laboratories - Immunitor - Inovio - Merck & Co - Nabi - Northwest Biotherapeutics - Novartis - PaxVax - Pfizer - Sanofi - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4n...roduct_and
NWBO: 5.80 (+0.07), MRK: 59.20 (-0.17), NVS: 92.62 (-0.15)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), MRK: 59.20 (-0.17), ABBV: 63.76 (-0.09), BMY: 58.61 (-0.11)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.71 (-0.20), GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), CNAT: 7.11 (+0.05), MRK: 59.20 (-0.17), RGLS: 19.99 (-0.48), ABBV: 63.76 (-0.09), BMY: 58.61 (-0.11), ENTA: 43.25 (+0.03)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 116.41 (-1.08), GILD: 107.19 (-0.82), MRK: 59.20 (-0.17), DNDN: 0.16 (+0.01), AZN: 74.19 (-0.01), TEVA: 58.34 (+0.15), ABBV: 63.76 (-0.09), GSK: 45.45 (-0.51), BMY: 58.61 (-0.11), NVS: 92.62 (-0.15)
Stocks Chart Out Narrow Losses; Vodafone Group Leads Nasdaq 100
at Investor's Business Daily - Tue Nov 11, 9:29AM CST
Thin gains quickly fizzled into light losses Tuesday as Veterans Day trading got underway. The Nasdaq dipped 0.1%. The S&P 500 and the Dow Jones industrial average dimmed a fraction each. Holiday trade was quiet, as expected, in the stock market...
FOSL: 112.92 (+9.17), YY: 80.28 (+0.50), HMIN: 30.44 (-0.25), ARRS: 28.40 (-0.41), AFSI: 51.26 (+0.60), MRK: 59.20 (-0.17), PE: 18.47 (+2.03), VOD: 35.16 (+0.36), HUM: 137.14 (+0.70)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.71 (-0.20), GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), CNAT: 7.11 (+0.05), MRK: 59.20 (-0.17), RGLS: 19.99 (-0.48), ABBV: 63.76 (-0.09), BMY: 58.61 (-0.11), ENTA: 43.25 (+0.03)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.71 (-0.20), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), AZN: 74.19 (-0.01), LLY: 67.64 (-0.21), GSK: 45.45 (-0.51)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.71 (-0.20), GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), CNAT: 7.11 (+0.05), MRK: 59.20 (-0.17), LGND: 57.17 (+0.27), RGLS: 19.99 (-0.48), ABBV: 63.77 (-0.08), BMY: 58.61 (-0.11), ENTA: 43.25 (+0.03)
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 11, 7:52AM CST
It's hard for any new hepatitis C drugs to compete with Gilead Sciences ' Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every clinical...
GILD: 107.19 (-0.82), MRK: 59.20 (-0.17), BMY: 58.61 (-0.11)
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naive and Difficult-to-Cure Patients
Business Wire - Tue Nov 11, 7:01AM CST
--First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015
MRK: 59.20 (-0.17)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.20 (-0.17), AZN: 74.19 (-0.01), AMGN: 162.18 (-0.24), TEVA: 58.34 (+0.15), THRX: 13.27 (+0.34), GSK: 45.45 (-0.51), SNY: 46.23 (-0.91), REGN: 400.24 (+1.88), NVS: 92.62 (-0.15)
'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 38.56 (+0.02), GD: 141.40 (+0.10), LMT: 186.99 (-0.13), RTN: 103.68 (-0.06), DDD: 33.97 (-0.64), NOC: 135.85 (-1.00), MO: 49.32 (+0.04), INTC: 33.35 (+0.04), KERX: 15.46 (-0.48), WPRT: 6.39 (+0.37), IBM: 162.30 (-1.00), MRK: 59.20 (-0.17), GM: 31.26 (-0.09), PG: 89.56 (-0.11), CAT: 102.87 (+0.34)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - 33 mins ago
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 108.72 (-0.19), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), AMGN: 162.18 (-0.24), MO: 49.31 (+0.03), CVX: 118.00 (-0.44)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 42.99 (-0.73), AGN: 196.23 (+0.89), HLF: 37.63 (+0.08), VRX: 130.90 (+0.87), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), LLY: 67.65 (-0.20)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), MRK: 59.20 (-0.17)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 59.20 (-0.17), NVS: 92.62 (-0.15)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.50 (-0.15), JNJ: 108.71 (-0.20), IDRA: 2.48 (-0.10), DERM: 16.07 (+0.04), MRK: 59.20 (-0.17), PFE: 30.42 (+0.10), AZN: 74.19 (-0.01), AMGN: 162.18 (-0.24), GSK: 45.45 (-0.51), HSP: 57.82 (+0.51), NVS: 92.62 (-0.15), CELG: 108.19 (+0.34)
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 107.19 (-0.82), MRK: 59.20 (-0.17)
Dow Index Dogs: 10% Bonus In 5 Lowest-Price, High-Yield Stocks
Fredrik Arnold - at Seeking Alpha - Tue Nov 11, 1:26PM CST
KO: 42.76 (+0.25), T: 35.38 (+0.28), GE: 26.56 (+0.18), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), MCD: 95.13 (-0.01), PG: 89.57 (-0.10), CVX: 118.00 (-0.44), VZ: 50.97 (+0.36), CSCO: 24.97 (-0.18)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - Tue Nov 11, 10:50AM CST
MRK: 59.20 (-0.17), AZN: 74.19 (-0.01), THRX: 13.27 (+0.34), TBPH: 17.88 (-0.08), GSK: 45.45 (-0.51)
Product and Pipeline Analysis of the Global Vaccines Market
M2 - Tue Nov 11, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/4nt5s9/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Vaccines Market " report to their offering. Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013. Key Findings:Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. - Vaccines are now available for prevention of about infectious diseases. - Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic. - Infectious disease vaccines-particularly viral vaccines-represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration. - One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases. - Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis. - The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction 4. Global Regulatory Oversight 5. Competitive Landscape 6. Competitive Landscape-Bacterial Vaccines 7. Competitive Landscape-Viral Vaccines 8. Competitive Landscape-Parasitic Vaccines 9. Competitive Landscape-Cancer Vaccines 10. Competitive Landscape-Allergy Vaccines 11. Competitive Landscape-Other Vaccines 12. Bacterial Vaccine Product Dashboard 13. Viral Vaccine Product Dashboard 14. Parasitic Vaccine Product Dashboard 15. Cancer Vaccine Product Dashboard 16. Allergy Vaccine Product Dashboard 17. Other Vaccine Products Dashboard 18. Timeline of Key Events 19. Conclusions Companies Mentioned - AFFiRiS - Archivel Farma - Biondvax - Bionor Pharma - Dendreon - GSK - Greer Laboratories - Immunitor - Inovio - Merck & Co - Nabi - Northwest Biotherapeutics - Novartis - PaxVax - Pfizer - Sanofi - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4n...roduct_and
NWBO: 5.80 (+0.07), MRK: 59.20 (-0.17), NVS: 92.62 (-0.15)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), MRK: 59.20 (-0.17), ABBV: 63.76 (-0.09), BMY: 58.61 (-0.11)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.71 (-0.20), GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), CNAT: 7.11 (+0.05), MRK: 59.20 (-0.17), RGLS: 19.99 (-0.48), ABBV: 63.76 (-0.09), BMY: 58.61 (-0.11), ENTA: 43.25 (+0.03)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 116.41 (-1.08), GILD: 107.19 (-0.82), MRK: 59.20 (-0.17), DNDN: 0.16 (+0.01), AZN: 74.19 (-0.01), TEVA: 58.34 (+0.15), ABBV: 63.76 (-0.09), GSK: 45.45 (-0.51), BMY: 58.61 (-0.11), NVS: 92.62 (-0.15)
Stocks Chart Out Narrow Losses; Vodafone Group Leads Nasdaq 100
at Investor's Business Daily - Tue Nov 11, 9:29AM CST
Thin gains quickly fizzled into light losses Tuesday as Veterans Day trading got underway. The Nasdaq dipped 0.1%. The S&P 500 and the Dow Jones industrial average dimmed a fraction each. Holiday trade was quiet, as expected, in the stock market...
FOSL: 112.92 (+9.17), YY: 80.28 (+0.50), HMIN: 30.44 (-0.25), ARRS: 28.40 (-0.41), AFSI: 51.26 (+0.60), MRK: 59.20 (-0.17), PE: 18.47 (+2.03), VOD: 35.16 (+0.36), HUM: 137.14 (+0.70)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.71 (-0.20), GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), CNAT: 7.11 (+0.05), MRK: 59.20 (-0.17), RGLS: 19.99 (-0.48), ABBV: 63.76 (-0.09), BMY: 58.61 (-0.11), ENTA: 43.25 (+0.03)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.71 (-0.20), PFE: 30.42 (+0.10), MRK: 59.20 (-0.17), AZN: 74.19 (-0.01), LLY: 67.64 (-0.21), GSK: 45.45 (-0.51)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.71 (-0.20), GILD: 107.19 (-0.82), ACHN: 14.48 (+2.00), CNAT: 7.11 (+0.05), MRK: 59.20 (-0.17), LGND: 57.17 (+0.27), RGLS: 19.99 (-0.48), ABBV: 63.77 (-0.08), BMY: 58.61 (-0.11), ENTA: 43.25 (+0.03)
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 11, 7:52AM CST
It's hard for any new hepatitis C drugs to compete with Gilead Sciences ' Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every clinical...
GILD: 107.19 (-0.82), MRK: 59.20 (-0.17), BMY: 58.61 (-0.11)
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naive and Difficult-to-Cure Patients
Business Wire - Tue Nov 11, 7:01AM CST
--First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015
MRK: 59.20 (-0.17)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.20 (-0.17), AZN: 74.19 (-0.01), AMGN: 162.18 (-0.24), TEVA: 58.34 (+0.15), THRX: 13.27 (+0.34), GSK: 45.45 (-0.51), SNY: 46.23 (-0.91), REGN: 400.24 (+1.88), NVS: 92.62 (-0.15)
'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 38.56 (+0.02), GD: 141.40 (+0.10), LMT: 186.99 (-0.13), RTN: 103.68 (-0.06), DDD: 33.97 (-0.64), NOC: 135.85 (-1.00), MO: 49.32 (+0.04), INTC: 33.35 (+0.04), KERX: 15.46 (-0.48), WPRT: 6.39 (+0.37), IBM: 162.30 (-1.00), MRK: 59.20 (-0.17), GM: 31.26 (-0.09), PG: 89.56 (-0.11), CAT: 102.87 (+0.34)
